Literature DB >> 11086118

Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Arvind H Patel1, Jonny Wood1, Francois Penin2, Jean Dubuisson3, J A McKeating4.   

Abstract

We compared the ability of two closely related truncated E2 glycoproteins (E2(660)) derived from hepatitis C virus (HCV) genotype 1a strains Glasgow (Gla) and H77c to bind a panel of conformation-dependent monoclonal antibodies (MAbs) and CD81. In contrast to H77c, Gla E2(660) formed disulfide-linked high molecular mass aggregates and failed to react with conformation-dependent MAbs and CD81. To delineate amino acid (aa) regions associated with protein aggregation and CD81 binding, several Gla-H77c E2(660) chimeric glycoproteins were constructed. Chimeras C1, C2 and C6, carrying aa 525-660 of Gla E2(660), produced disulfide-linked aggregates and failed to bind CD81 and conformation-dependent MAbs, suggesting that amino acids within this region are responsible for protein misfolding. The presence of Gla hypervariable region 1 (aa 384-406) on H77 E2(660), chimera C4, had no effect on protein folding or CD81 binding. Chimeras C3 and C5, carrying aa 384-524 or 407-524 of Gla E2(660), respectively, were recognized by conformation-dependent MAbs and yet failed to bind CD81, suggesting that amino acids in region 407-524 are important in modulating CD81 interaction without affecting antigen folding. Comparison of Gla and H77c E2(660) aa sequences with those of genotype 1a and divergent genotypes identified a number of variant amino acids, including two putative N-linked glycosylation sites at positions 476 and 532. However, introduction of G476N-G478S and/or D532N in Gla E2(660) had no effect on antigenicity or aggregation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086118     DOI: 10.1099/0022-1317-81-12-2873

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  39 in total

1.  Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice.

Authors:  Gillian Martínez-Donato; Yanelis Capdesuñer; Nelson Acosta-Rivero; Armando Rodríguez; Juan Morales-Grillo; Eduardo Martínez; Marleny González; Julio C Alvarez-Obregon; Santiago Dueñas-Carrera
Journal:  Mol Biotechnol       Date:  2007-03       Impact factor: 2.695

Review 2.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

3.  Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry.

Authors:  Guillemette Maurin; Judith Fresquet; Ophélia Granio; Czeslaw Wychowski; François-Loïc Cosset; Dimitri Lavillette
Journal:  J Biol Chem       Date:  2011-05-09       Impact factor: 5.157

4.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.

Authors:  Claire Bertaux; Tatjana Dragic
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 8.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.

Authors:  Shazia Rafique; Muhammad Idrees; Amjad Ali; Kashif Iqbal Sahibzada; Muhammad Iqbal
Journal:  Mol Biol Rep       Date:  2014-02-19       Impact factor: 2.316

10.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

Authors:  Jeroen Witteveldt; Matthew J Evans; Julia Bitzegeio; George Koutsoudakis; Ania M Owsianka; Allan G N Angus; Zhen-Yong Keck; Steven K H Foung; Thomas Pietschmann; Charles M Rice; Arvind H Patel
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.